CryoPort (NASDAQ:CYRX) Stock Price Up 4.7% – What’s Next?

CryoPort, Inc. (NASDAQ:CYRX) shares rose 4.7% during mid-day trading on Tuesday . The stock traded as high as $16.21 and last traded at $16.2830. 9,832 shares were traded during trading, a decline of 98% from the average session volume of 579,522 shares. The stock had previously closed at $15.55.

Analyst Ratings Changes

A number of research firms have recently weighed in on CYRX. Jefferies Financial Group set a $13.50 price objective on CryoPort in a research note on Monday, June 8th. BTIG Research increased their price target on shares of CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Needham & Company LLC raised their price target on shares of CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Roth Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of CryoPort in a research note on Friday, August 7th. Finally, Weiss Ratings lowered shares of CryoPort from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 17th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.00.

CryoPort Price Performance

The business has a 50 day moving average of $15.70 and a 200 day moving average of $13.13. The company has a market cap of $821.54 million, a PE ratio of -18.05 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The company had revenue of $48.97 million for the quarter, compared to analysts’ expectations of $48.18 million. Sell-side analysts forecast that CryoPort, Inc. will post -0.83 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the transaction, the chief executive officer owned 1,201,814 shares in the company, valued at $17,919,046.74. The trade was a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by corporate insiders.

Institutional Trading of CryoPort

Institutional investors and hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP purchased a new position in shares of CryoPort during the 2nd quarter worth approximately $518,000. Squarepoint Ops LLC lifted its stake in shares of CryoPort by 685.1% in the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock valued at $5,784,000 after purchasing an additional 321,497 shares during the period. Highland Investment Advisors LLC purchased a new position in shares of CryoPort in the 2nd quarter valued at approximately $306,000. Kerrisdale Advisers LLC purchased a new position in shares of CryoPort in the 2nd quarter valued at approximately $355,000. Finally, Headlands Technologies LLC boosted its position in shares of CryoPort by 14.5% during the second quarter. Headlands Technologies LLC now owns 38,742 shares of the company’s stock valued at $608,000 after purchasing an additional 4,906 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Company Profile

Cryoport, Inc (NASDAQ: CYRX) provides temperature-controlled logistics and supply-chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials, including cell and gene therapies, biologics, vaccines, clinical-trial materials and reproductive tissues.

Its offerings include specialized cryogenic and refrigerated shipping systems, monitoring and tracking technologies, logistics coordination, packaging and storage services, and related bioservices.